BioSpace News Archive

The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, publishes sales for the first half of 2020.

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the results of an interim analysis from the company’s post-market BRAVO study evaluating the clinical performance of OviTex for the treatment of ventral hernias.

ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics.

Subsidiary to Advance Commercial Development of Diagnostic Tests for Virology, COVID-19, Oncology

LGC announced the acquisition of The Native Antigen Company, one of the world’s leading suppliers of high quality infectious disease antigens and antibodies.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release second-quarter 2020 financial results before the market opens on Thursday, July 23, 2020, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and commercial plans

Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in animal cells

Oncologie, Inc. announced an expansion of its management team with the appointments of Matthew Osborne as Chief Financial Officer, Hagop Youssoufian, M.D., as Interim Chief Medical Officer, Bill McDonald, Ph.D., as Vice President of Chemistry, Manufacturing and Controls, as well as the promotion of Kerry Culm-Merdek, Ph.D., to Vice President of Clinical Development.

Altimmune, Inc. announced that it has entered into a teaming agreement with DynPort Vaccine Company, a General Dynamics Information Technology company, to coordinate U.S. Government funding efforts and, if successful, to provide program management, drug development activity integration, and regulatory support for AdCOVID, Altimmune’s single-dose intranasal COVID-19 vaccine candidate.